You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

BIAXIN XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Biaxin Xl patents expire, and what generic alternatives are available?

Biaxin Xl is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in BIAXIN XL is clarithromycin. There are twenty-one drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Biaxin Xl

A generic version of BIAXIN XL was approved as clarithromycin by ACTAVIS LABS FL INC on June 24th, 2004.

  Try a Trial

Drug patent expirations by year for BIAXIN XL
Recent Clinical Trials for BIAXIN XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2
Emory UniversityPhase 2
Nicolaas Bohnen, MD, PhDPhase 1/Phase 2

See all BIAXIN XL clinical trials

US Patents and Regulatory Information for BIAXIN XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BIAXIN XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ⤷  Try a Trial ⤷  Try a Trial
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ⤷  Try a Trial ⤷  Try a Trial
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BIAXIN XL

See the table below for patents covering BIAXIN XL around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 347199 ⤷  Try a Trial
European Patent Office 1223949 ⤷  Try a Trial
European Patent Office 0973527 FORMULATIONS DE CLARITHROMYCINE A LIBERATION PROLONGEE (EXTENDED RELEASE FORMULATIONS OF CLARITHROMYCIN) ⤷  Try a Trial
China 100408044 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 9846239 ⤷  Try a Trial
Portugal 973527 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BIAXIN XL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0328535 96C0021 Belgium ⤷  Try a Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.